

Evaluation of Antibiotic Resistance of Patients with Ventriculoperitoneal Shunt Infection

Ferhat Karakoç¹  · Özhan Orhan²  · Selda Erdinç Karakoç³  · Fesih Aktar⁴ 

¹Elâzığ Fırat University, Faculty of Medicine, Pediatrics, Elâzığ, Turkey

²Mardin Artuklu University, Faculty of Medicine, Pediatrics, Mardin, Turkey

³Gazi Yaşargil Training and Research Hospital, Pediatrics, Diyarbakır, Turkey

⁴Diyarbakır Dicle University, Faculty of Medicine, Pediatrics, Diyarbakır, Turkey

Introduction: Cerebrospinal fluid (CSF) shunts carry CSF to other body parts for absorption in cases of hydrocephalus. However, infections seen in these systems are serious problems that cause the shunt to fail and cause high mortality. The study aimed to evaluate the epidemiological, clinical, and laboratory findings of cases with a ventriculoperitoneal shunt (VPS) due to hydrocephalus and who developed shunt infection and to determine the antibiotic resistance of microorganisms that cause shunt infection.

Materials and Methods: This study was conducted in Dicle University Faculty of Medicine, Department of Child Health and Diseases, Department of Pediatric Infectious Diseases, between January 2014 and November 2016. Eighty-one cases of VPS infection, aged between 0 and 18, regardless of gender, were analyzed retrospectively.

Results: Gram-positive and negative microorganisms were grown in the CSF culture in 64.1% and 35.9% of patients, respectively. The most commonly grown gram-positive microorganism was coagulase-negative staphylococcus, while the most commonly grown gram-negative microorganism was *Acinetobacter* sp. The most effective antibiotics against gram-positive bacteria were vancomycin, teicoplanin, and linezolid. The most effective antibiotics against gram-negative bacteria were colimycin, amikacin, ceftazidime, and meropenem. 21% of the cases died.

Conclusion: If VPS infections are not treated correctly, especially in childhood, they progress to severe mortality and morbidity. Therefore, first of all, measures should be taken to prevent the formation of shunt infections, and we believe that long-term hospitalization rates and high treatment costs can be avoided by choosing appropriate and correct antibiotic regimens to prevent increasing antibiotic resistance.

Keywords: Antibiotic resistance; shunt infection; mortality; ventriculoperitoneal shunt

Introduction

Today, in the treatment of hydrocephalus, shunt systems are used to drain CSF into another body cavity to reduce intracranial pressure (1). These systems bring some severe complications along with high treatment costs.

The most common complications primarily seen in the first months following surgery are shunt obstruction, hematoma, infection, shunt disconnection and slit ventricle syndrome (2, 3). Ventriculoperitoneal shunt (VPS) infection is a

Corresponding Author: Ozhan ORHAN; Mardin Artuklu University Faculty of Medicine, Pediatrics, Mardin, Turkey

E-mail: ozhan.orhan@hotmail.com.tr

ORCID: 0000-0002-3042-6972

Received: Mar 26, 2023 **Accepted:** Ap 9, 2023

Published: June 9, 2023

This is an Open Access article distributed under the terms of Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, or reproduction in any area, original work is properly cited.

The Ulutas Medical Journal © 2023



severe problem that causes the shunt to fail and is seen with a frequency of 5-15% (4).

Infection is the most serious and most common shunt complication. Shunt infections can lead to mortality and neurological deficits up to 30-40%. Colonization on shunt elements during surgery is the most accepted route. Therefore, 80% of shunt infections occur in the first three months and 90% in the first six months, unlike the mechanical complications of the shunt. The most extensive paediatric series published in 2012 determined that shunt infections occur between 6 days and eight months after surgery (5-7).

The parenteral antibiotic to be administered is selected under the guidance of CSF Gram staining and culture results. These results also guide empirical antibiotic treatments. Accordingly, a combination of vancomycin (15-20 mg/kg IV; every 8-12 hours; each dose not exceeding 2 g) and a drug effective against Gram-negative microorganisms is used empirically. These treatments are rearranged in light of the culture results. There are no randomized, prospective studies to determine the optimal duration of antibiotic therapy and time for shunt change. Some approaches vary according to clinical situations (8).

The present study evaluated the clinical and demographic characteristics of patients who had VPS in our clinic due to hydrocephalus and developed shunt infection. In addition, we analyzed the detection of the microorganism causing the shunt infection, the detection of antibiotic resistance against the microorganism, and the selection of the appropriate antibiotic.

Materials and Methods

Ethical Statement

Between January 2014 and November 2016, 81 patients who had VPS due to hydrocephalus in the Dicle University Faculty of Medicine Paediatric Infection Clinic and developed shunt infection were analyzed retrospectively. This study was approved by the Dicle University

Faculty of Medicine, the Non-Invasive Clinical Research Ethics Committee with decision number 15 dated 12.01.2017.

Inclusion criteria: Consecutive patients with VPS infection, aged 0 to 18 years, regardless of gender, were included in the study. Cases the files that could not be accessed in hospital records, had missing data, and did not meet the diagnostic criteria for VPS infection were excluded from the study. All cases included in the study were evaluated with a standardized clinical follow-up form. The diagnosis of VPS infection was made by CSF analysis, blood and CSF cultures, and imaging methods. From the hospital file records of all cases, demographic data (age, gender, shunt insertion age, reason for shunt insertion), clinical findings, length of hospitalization, presence of growth in culture, growing microorganisms, culture antibiogram results, treatments given, and their durations, post-treatment follow-up and data regarding the results were recorded. Microorganisms grown in cases with positive CSF, antibiotic resistance rates according to antibiogram results, treatments, duration, and mortality rates were evaluated.

Statistical Analysis

The data collected in the study were analyzed using the statistical software package SPSS 18 (Statistical Package for the Social Sciences IBM®, Chicago, IL, USA). Whether the variables showed normal distribution was evaluated using histogram and analytical (Kolmogorov-Smirnov test) methods. Descriptive statistics for continuous variables, among the features emphasized, were expressed as mean± standard deviation, minimum and maximum values, while categorical variables were expressed as number and percentage. Student-t test was used to compare independent groups. Statistical analyses of the variables determined by the ratio were performed with the chi-square test. $P < 0.05$ was considered significant in the statistical evaluation.

Results

43 (53.1%) were female, and 38 (46.9%) were male. The mean age of the cases was 25.7 ± 39.1 months (1-164 months). The mean hospital stay was 40.1 ± 37.6 days (14-52). A shunt catheter was inserted in 62 (76.5%) cases with VPS infection at 0-1 months, while a shunt catheter was inserted in 12 (14.8%) at 1-3 months of age. The most common reason for shunt catheter insertion was hydrocephalus (95.1%). Demographic characteristic and clinical findings of the cases are given in Table 1.

Table 1. Demographic and clinical data

Variables	n(%) / Mean $\pm$ Sd
Sex	
Female	43 (53,1)
Male	38 (46,9)
Average age (months)	25.7 $\pm$ 39.1
Hospitalization period (days)	40.1 $\pm$ 37.6
The age of having VP shunt catheter	
0-1 months	62 (76,5)
1-3 months	12 (14,8)
3-6 months	4 (4,9)
6-12 months	2 (2,5)
>12 months	1 (1,2)
The reason of VP shunt catheter	
Hydrocephalus	78 (96,3)
Central nervous system tumour	2 (2,5)
Infection(meningitis/encephalitis)	1 (1,2)

79 (%97.5) presented findings of fever, 76 (%93.8) of vomiting, 60 (%74.1) of anterior fontanel bulging, 59 (72.8%) of abdominal symptoms, 67 (67.9%) of shunt leakage, 42 (51.9%) of altered consciousness, 38 (46.9%) of convulsion, and 36 (44.4%) of meningeal irritation. Among CFS, BOS was the source of infection in 53 (65.4%), urine, wound, and/or tracheal aspirate in 14 (17.3%), blood in 11 (13.6%), and catheter (shunt and/or central venous catheter) three (3.7%). Culture positivity was detected in all 81 (100%). Of the cases with growth in CSF, gram-positive microorganisms were grown in 34 (64,1%), and gram-negative microorganisms were grown in 19 (35.9%).

Table 2. Antibigram resistance rates of gram negative and gram positive microorganisms

Antibiotic	Gram positive, %	Gram negative, %
Amikacin	-	26,3
Clindamycin	70,6	89,5
Colimycin	-	10,5
Linezolid	35,3	-
Meropenem	38,2	36,8
Cefotaxime	73,5	73,7
Ceftazidime	67,6	26,3
Ceftriaxone	73,5	73,7
Ciprofloxacin	-	63,2
Sulperazone	47,1	31,6
Tazobactam	73,5	47,4
Teicoplanin	32,4	-
Vancomycin	32,4	-

In which gram-positive microorganisms grew, coagulase-negative staphylococci grew in 23 (43.4%), methicillin-resistant *staphylococcus aureus* (MRSA) in six (11.3%) and *staphylococcus aureus* in five (9.4%). Of the cases where gram-negative microorganisms grew, *acinetobacter spp.* grew in 12 (22.6%), *klebsiella spp.* in three (5.7%), *escherichia coli* in three (5.7%) and *Pseudomonas spp* in one (1.9%). Microorganisms grown in CSF are given in Figure 1.

When the culture antibiogram results with CSF positivity were evaluated, the antibiotics with the highest resistance among gram-positive bacteria were ceftriaxone (73.5%), cefotaxime (73.5%), tazobactam (73.5%), clindamycin (70.6%), and ceftazidime (67.6%), respectively. In comparison, the most effective antibiotics were vancomycin (67.6%), teicoplanin (67.6%), linezolid (64.7%), meropenem (61.8%), and Sulperazone (52.9%). The antibiotics with the highest resistance among gram-negative bacteria were clindamycin (89.5%), ceftriaxone (73.7%), cefotaxime (73.7%), and ciprofloxacin (63.2%), respectively, while the most effective antibiotics were colimycin (89.5%), amikacin (73.7%), ceftazidime (73.7%), Sulperazone (68.4%), and meropenem (63.2%) and tazobactam (52.6%) (Table 2).




Figure-1

The mean duration of antibiotic use in all cases was 32.6 ± 27.8 days (6-170 days), and the mean duration of antifungal use was 4.7 ± 6.5 days (0-16 days), while the mean duration of antibiotic use in cases with positive CSF was 33.8 ± 29.5 days (7-170 days). Antibiotic changes were made during follow-up in 48 cases (59.3%). 17 (21%) of the cases included in the study died.

Discussion

VP shunts are the most effective and frequently used method in treatment of hydrocephalus. The most common complications are shunt occlusions and shunt infections (9,10,11). When the distribution of hydrocephalus cases in the paediatric age group by gender was examined, it was reported that shunt infections were more common in males, although shunt infections were more common in females in some studies (12,13,14). In our study, 46.9% of our cases were male, and 53.1% were female.

VPS and fever should be evaluated for shunt infection (15). Fever is seen in 42-87% of all patients with a shunt infection. Headache, vomiting, and lethargy may be other signs of

2014, Gülşen et al. reported that the most common clinical finding in patients with shunt infection was fever at a rate of 84.5%, nausea and vomiting (52%) along with fever complaints, and redness and restlessness along the shunt tracing (17). In our study, 97.5% of our cases had a fever. In addition, findings of vomiting, anterior fontanel bulging, abdominal symptom, shunt leakage, change in consciousness, convulsions, and meningeal irritation were detected in 93.8%, 74.1%, 72.8%, 67.9%, 51.9%, 46.9%, and 44.4% of our patients, respectively.

In cases with shunt infection, coagulase-negative staphylococci *S. epidermidis*, *S. capitis*, and *S. hominis* are isolated in 40-70% of cases. *S. aureus* is the second most frequently isolated pathogen, varying between 10-40%. Of the other gram-positive organisms, group A streptococci, enterococcus, *Propionibacterium*, *Corynebacterium*, *Haemophilus influenzae*, *streptococcus pneumoniae*, and *Neisseria meningitidis* are also causative pathogens (18,19). Gram-negative bacteria are causative in 5-25% of cases; *E. coli*, *Klebsiella*, and *Proteus* are common, while *pseudomonas* and

Acinetobacter are less common. Gram-negative bacteria are the more common (40-60%) causative pathogens in nosocomial VPS meningitis. In the studies conducted, *E. coli* were reported at a rate of 52%, *K. pneumoniae* at 22%, and *Proteus spp.* 9%, *P. aeruginosa* 4% and *Enterobacter* 4% (20). Kulkarni et al. reported that 48.4% of the microorganisms grown in the culture were *S. aureus*, and 38.7% were coagulase-negative staphylococci (21). In our study, culture positivity was found in all 81 cases. Of the cases with growth in CSF culture, gram-positive microorganisms were grown in 64.1%, and gram-negative microorganisms were grown in 35.9%. Of the cases in which gram-positive microorganism grew, coagulase-negative staphylococci grew in 43.4%, methicillin-resistant *staphylococcus aureus* (MRSA) in 11.3%, and *staphylococcus aureus* in 9.4%, of the cases where gram-negative microorganisms grew *Acinetobacter spp.* Growth is seen in 22.6%, *klebsiella spp.* 5.7%, *escherichia coli* in 5.7% and *psedomonas* in 1.9%.

The Infectious Diseases Society of America (IDSA) treatment guideline for VPS meningitis published in 2004 recommends combining a glycopeptide with ceftazidime, cefepime, or meropenem as empirical antibiotic therapy (22).

The CSF profile determines the duration of antibiotic treatment, the causative microorganism, and the shunt removal. In infections where the causative agent is detected as CNS, an average of 7 days of treatment is sufficient after removal of the shunt. This period can be kept shorter (3-5 days) under conditions where CSF findings are expected from the beginning. Treatment times should be longer in infections caused by more virulent microorganisms and in cases where the shunt cannot be removed (23,24). While the mean duration of antibiotic use in our patients was 32.6 ± 27.8 days, the mean duration in cases with positive CSF culture was 33.8 ± 29.5 days. While antibiotics were used in all of our cases, antibiotic changes were

made in 59.3% of them during follow-up. In the study conducted by Demir in 2013, it was reported that the antibiotic susceptibility of gram-positive microorganisms was mainly found to have ampicillin, erythromycin, oxacillin, and ceftriaxone resistance. In the same study, the most ciprofloxacin, amikacin, and meropenem resistance was observed against gram-negative bacteria (25). In the study conducted by Çavuşoğlu in 2008, the presence of penicillin, ampicillin, erythromycin, and oxacillin resistance in antibiotic susceptibility of gram-positive microorganisms was reported. In the same study, the ampicillin, amoxicillin-clavulanic acid, and cefoxitin resistance was determined to be the most against gram-negative microorganisms (26). In our study, the antibiotics with the highest resistance in gram-positive bacterial growth in the CSF culture were ceftriaxone, cefotaxime, tazobactam, clindamycin, and ceftazidime, respectively.

In contrast, those with the least resistance were vancomycin, teicoplanin, linezolid, meropenem, and sulfentrazone. Among gram-negative bacteria, the antibiotics with the most resistance were clindamycin, ceftriaxone, cefotaxime, and ciprofloxacin, respectively, while those with the least resistance against were sulperazone, meropenem, colimycin, amikacin, ceftazidime and tazobactam. In our study, vancomycin, ceftriaxone, meropenem, linezolid, cefotaxime, teicoplanin, sulperazone, and clindamycin were used in antibiotic combinations, in order of frequency, in cases where gram-positive microorganisms were grown. Antibiotic combinations included meropenem, ceftriaxone, colimycin, amikacin, cefotaxime, tazobactam, and sulfentrazone in cases where gram-negative microorganisms were grown. Considering shunt-related infection, we think that empirically starting treatment with gram-positive vancomycin together with colistin or meropenem may be an appropriate initial treatment until culture antibiogram results are obtained.

Conclusion

If shunt infections are not treated properly, especially in childhood, they progress with severe mortality and morbidity for the rest of their lives. Therefore, first of all, measures should be taken to prevent the formation of shunt infections, and we believe that long-term hospitalization and high treatment costs can be avoided by choosing appropriate and correct regimens to prevent increasing antibiotic resistance. Microbiological data are vital for the correct empirical treatment approach. In this way, intensive antibiotic use and subsequent high resistance rates will be controlled.

Conflict of Interest

The authors declare no conflict of interest.

Reference

1. Rekate HL. Treatment of hydrocephalus, In: Albright L, Pollack I, Adelson D (eds). Principles and Practice of Pediatric Neurosurgery. New York: Thieme Medical Publishers; 1999. p.45-73
2. Weprin BE, Swift DM. Complications of ventricular shunts. Techniques in Neurosurgery 2002;7:224-42
3. Yılmaz A, Hacı AG, Müslüman AM, Çolak İ, Şahin Y, Aydın Y. Ventriküloperitoneal Şant Disfonksiyonları. Türk Nöroşirürji Dergisi 2006;16:150-5
4. Vanaclocha V, Saiz-Sapena N, Leiva J. Shunt malfunction in relation to shunt infection. Acta Neurochir 1996;138:829-34
5. Erşahin Y. Beyin Omurilik sıvısı şant enfeksiyonları. Türk Nöroşirürji Dergisi 1999;9:12-20
6. Hirsch JF. Surgery of hydrocephalus: Past, present and future. Acta Neurochir (Wien) 1992;116:155-160
7. Lee JK, Seok JY, Lee JH, Choi EH, Phi JH, Kim SK, Wang KC, Lee HJ. Incidence and risk factors of ventriculoperitoneal shunt infections in children: A study of 333 consecutive shunts in 6 years. J Korean Med Sci 2012;27(12):1563-1568
8. Tunkel A. R., Hartman B. J., Kaplan S. L., Kaufman B. A., Roos K. L., Scheld W. M., & Whitley R. J. (2004). Practice guidelines for the management of bacterial meningitis. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, 39(9), 1267-1284
9. Brydon HL, Hayward R, Harkness W, Bayston R. Does the cerebrospinal fluid protein concentration increase the risk of shunt complications? British Journal of Neurosurgery 1996;10(3): 267-273
10. Çelik İ, Erol FS, Cihangiroğlu M, Akdemir İ, Tiftikçi M. Ventriküloperitoneal şant enfeksiyonlu olguların değerlendirme. ANKEM Derg 2003;17(1):60-64
11. Kontny U, et al. CSF shunt infections in children: Infection, 1993;21(2): 89-92
12. Güzelbağ E, Erşahin Y ve Mutluer S. Cerebrospinal fluid shunt complications: The Turkish Journal of Pediatrics, 1997;39:363-71
13. Choux M, et al. Shunt implantation: reducing the incidence of shunt infection: J Neurosurg, 1992;77:875-80
14. Özbek Z, Özkara E, Vural M. A Retrospective Analyses of Newborns Operated Due to Midline Spinal Closure Defect: A Single Center Experience. Journal of Clinical and Analytical Medicine. 2017;1-4
15. Noetzel MJ, Baker RP. Shunt fluid examination: risks and benefits in the evaluation of shunt malfunction and infection. J Neurosurg 1984;61(2):328-32
16. Walters B, Hofman H, Hendrick E, Humphreys RP: Cerebrospinal fluid shunt infection: Influences on initial management and subsequent outcome. J Neurosurgery 1984; 60:1014-2
17. Gülşen İ, Ak H, Aycan A, Atalay T, Enver Söşuncu E, Akyol Me, Kuyumcu F, Arslan M. Pediatrik şant enfeksiyonları: 105 olguluk çift merkezli çalışma. Bozok Tıp Derg 2015;5(1):13-7
18. Filka J, Huttova M, Tuharsky J, et al. Nosocomial meningitis in children after ventriculoperitoneal shunt insertion. Acta Paediatr 1999;88:576-8
19. Stamos JK, Kaufman BA, Yögev R. Ventriculoperitoneal shunt infections with Gram-negative bacteria. Neurosurgery 1993; 33:858-62
20. Arthur AS, Whitehead WE, Kestle JR. Duration of antibiotic therapy for the treatment of shunt infection: a surgeon and patient survey. Pediatr Neurosurg 2002;36(5):256-9
21. Kulkarni AV, Drake JM and Lamberti-Pasculli M. Cerebrospinal fluid shunt infection: a prospective study of risk factors. J Neurosurg; 2001;94:195-201
22. Anderson, Evan J., and Ram Yögev. "A rational approach to the management of ventricular shunt infections." The Pediatric infectious disease journal 24.6 (2005): 557-558
23. Fong IW. Staphylococcal central nervous system infections treated with Cloxacillin. J Antimicrob Chemother.1983;12:607-612
24. Pfausler B, Haring HP, Kampf A, Wissel J, Schöber M, Schmutzhard E. CSF pharmacokinetics of intraventricular vancomycin in patients with shunt ventriculitis associated with external CSF drainage. Clin. Inf. Dis. 1997;25:733-5
25. Demir V. Ventriküloperitoneal Şant Enfeksiyonlarının Etiyolojik ve Prognostik Açısından Değerlendirilmesi. Tıpta Uzmanlık Tezi, Diyarbakır. 2013
26. Çavuşoğlu F. Ventriküloperitoneal Şant Enfeksiyonu Sebebiyle Tedavi Edilen Çocukların Retrospektif Değerlendirilmesi. Tıpta Uzmanlık Tezi, İstanbul. 2008

Contact Details

Ferhat KARAKOC, MD

Elazığ Fırat University Faculty of
Medicine, Pediatrics, Elazığ, Turkey
ORCID: 0000-0009-2894-2036
E-mail: drferhat32@gmail.com

Ozhan ORHAN, MD

Mardin Artuklu University, Faculty
of Medicine, Pediatrics, Mardin, Turkey
ORCID: 0000-0002-3042-6972
E-mail: ozhan.orhan@hotmail.com.tr

Selda Erdinc KARAKOC, MD

Gazi Yaşargil Training and Research
Hospital, Pediatrics, Diyarbakır, Turkey
ORCID: 0000-0009-9734-7418
E-mail: seldinc@hotmail.com

Fesih AKTAR, MD

Diyarbakır Dicle University Faculty
of Medicine, Pediatrics, Diyarbakır, Turkey
ORCID: 0000-0002-0760-5681
E-Mail: fesihaktar@yahoo.com

How to cite?

Karakoc F, Orhan O, Karakoc SE, Aktar F.
Evaluation of Antibiotic Resistance of Patients
with Ventriculoperitoneal Shunt Infection.
Ulutas Med J. 2023;9(2):74-80

DOI: 10.5455/umj.20230320013100